Synthesis of Some 4,5-Dihydrothieno[*3,2-e*][1,2,4]Triazolo[*4,3-a*] Pyrimidine-2-Carboxamides as Anti-Inflammatory and Analgesic Agents

Omaima G. Shaaban[1], Ola H. Rizk[1,*], Aida E. Bayad[2] and Ibrahim M.El-Ashmawy[3]

[1]Department of Pharmaceutical Chemistry, Faculty of Pharmacy, University of Alexandria, Alexandria 21521, Egypt; [2]Univ. Fellow, Veterinary Services Unit, Faculty of Veterinary Medicine, University of Alexandria, Egypt; [3]Department of Veterinary Medicine, Faculty of Agricultural and Veterinary Medicine, Qassim University, Buraydah 1482, Al-Qassim, Saudi Arabia

Abstract: A new series 4,5-dihydrothieno[*3,2-e*][1,2,4]triazolo[*4,3-a*]pyrimidine-2-carboxamide was synthesized. Twenty one newly synthesized compounds were investigated for their anti-inflammatory and analgesic activity using acute and subacute formalin-induced paw edema models and diclofenac Na as a reference. The acute toxicity (ALD_{50}) and ulcerogenic effects of the active compounds were also determined. The thienotriazolopyrimidines **10a**, **10c** and **11c** were found to exhibit remarkable anti-inflammatory activity at both models in addition to good analgesic activity with a delayed onset of action. Moreover, the active compounds showed high GI safety level and are well tolerated by experimental animals with high safety margin (ALD_{50} > 0.4 g/kg). Docking study using Molecular Operating Environment (MOE) version 2008.10 into COX-2 has been made for derivatives of highest anti-inflammatory activity.

Thienotriazolopyrimidine derivatives with promising anti-inflammatory and analgesic activities.

Keywords: Synthesis, thienotriazolopyrimidines, antiinflammatory activity, ulcerogenic effect, acute toxicity, analgesic activity, docking.

INTRODUCTION

It is well known that prolonged use of non steroidal anti-inflammatory drugs (NSAIDs) is associated with several side effects such as gastrointestinal mucosal damage, bleeding, intolerance and renal toxicity [1,2]. Therefore, production of safer and more active NSAIDs and analgesic drugs is still needed.

It is evident from the literature that thienopyrimidines, played an essential role in several biological processes and have considerable chemical and pharmacological importance. They were found to display antiviral [3, 4], antimicrobial [5-8], anticancer [5, 9-11], analgesic and anti-inflammatory activities [12-16].

In our ongoing medicinal chemistry research programme, we have demonstrated that some dihydrothieno[*2,3-d*]pyrimidine and tetrahydrothieno[*3,2-e*][1,2,4]triazolo[*4,3-a*]pyrimidine derivatives (Fig. **1**, **A-C**)[17], exhibited anti-inflammatory activity equivalent to diclofenac sodium in the inflammatory models in addition to their high safety level and low ulcerogenicity. Whereas, 2-substituted-6,7-dimethylthieno[*2,3-d*][1,2,4]triazolo[*1,5-a*]pyrimidinones and dihydrothieno[*2,3-d*][1,2,4] triazolo[*1,5-a*]pyrimidin-2-yl) acetamide (Fig. **2**, **D** and **E**) [18] exhibited good analgesic and anti-inflammatory activities.

Based on these findings we extended our approach to the synthesis and pharmacological investigation of some new dihydrothieno[*3,2-e*][1,2,4]triazolo[*4,3-a*]pyrimidine-2-carboxamides as anti-inflammatory and analgesic agents. To explore the biological profile of the newly synthesized compounds, the substitution pattern at position 8 of the

*Address correspondence to this author at the Department of Pharmaceutical Chemistry, Faculty of Pharmacy, University of Alexandria, Alexandria 21521, Egypt; Tel: +(203)4871317 ; Fax: + (203)4873273; Email: olarizk@yahoo.com

Fig. (1). Chemical structures of previously reported anti-inflammatory thienopyrimidines and fused thienopyrimidines.

Fig. (2). Chemical structures of previously reported anti-inflammatory and analgesic thienotriazolopyrimidines.

thienotriazolopyrimidine ring system was selected so as to confer different electronic environment that would affect the lipophilicity, and hence the activity of the target molecules. In addition to the anti-inflammatory and analgesic activities, the ulcerogenicity and acute toxicity of the most active compounds were also investigated. A molecular docking study was also performed for the most active compounds in a trial to investigate the possible mode of action of these compounds.

MATERIALS AND METHODS

Chemistry

All reagents and solvents were purchased from commercial suppliers and were dried and purified when necessary by standard techniques.

Melting points were determined in open glass capillaries using Stuart capillary melting point apparatus (Stuart Scientific Stone, Staffordshire, UK) and are uncorrected. Infrared (IR) spectra were recorded on Perkin-Elmer 1430 infrared spectrophotometer (Perkin Elmer, Beaconsfield, UK) and

measured by ύ cm^{-1} scale using KBr cell. ^{1}H-NMR spectra were scanned on Varian Mercury VX-300, using tetramethylsilane (TMS) as internal standard and DMSO-d$_6$ as the solvent (chemical shifts are given in δ ppm). Splitting patterns were designated as follows: s: singlet; d: doublet; dd: doublet of doublet; t: triplet; m: multiplet. ^{13}C-NMR proton decoupled spectra were recorded on a Varian Mercury VX-300 spectrometer in DMSO-d$_6$ and measured in δ scale. Mass spectra were run on a Finnigan mass spectrometer model SSQ/7000 (70 eV) or on a gas chromatograph/mass spectrometer Schimadzu GCMS-QP 2010 Plus (70 eV). Microanalyses were performed at the Microanalytical Unit, Faculty of Science, Cairo University, Egypt and the found values were within ±0.4% of the theoretical values. Follow up of the reactions and checking the purity of the compounds was made by thin layer chromatography (TLC) on silica gel-precoated aluminium sheets (Type 60 GF254; Merck; Germany) and the spots were detected by exposure to UV lamp at λ 254 nm for few seconds. The key intermediate **5** was synthesized as described in Ref. [17]

5- Benzyl-3-methyl-8-{[2-(substituted amino)-2-oxoethyl]sulfanyl}-4-oxo-4,5-dihydrothieno[*3,2-e*][1,2,4]triazolo[*4,3-a*]pyrimidine-2-carboxamides (7a-f)

A mixture of **5** (0.37 g, 1 mmol) , appropriate 2-chloro-N-substituted acetamides **6** (1 mmol) and anhydrous potassium carbonate (0.14 g, 1 mmol) in dry acetone (20 ml) was stirred and heated under reflux for 10 hours . The mixture was then cooled, poured into ice-cold water, filtered and the solid obtained was dried and crystallized from DMF.

5- Benzyl-3-methyl-8-{[2-(phenylamino)-2-oxoethyl]sulfanyl}-4-oxo-4,5-dihydrothieno[*3,2-e*][1,2,4]triazolo[*4,3-a*]pyrimidine-2-carboxamide (7a)

M.P. 276-8 °C; Yield 70%; IR (KBr, cm^{-1}): 3395, 3345 (NH$_2$), 3277 (NH), 1679, 1658 (C=O), 1589 (C=N), 1265, 1083 (C-S-C). ^{1}H-NMR (δ ppm): 2.68 (s, 3H, CH$_3$), 3.89 (s, 2H, SCH$_2$), 5.28 (s, 2H, N-CH$_2$), 6.98-7.37 (m, 10H, two phenyl-H), 7.75 (s, 2H, NH$_2$, D$_2$O exchangeable), 9.98 (s, 1H, NH, D$_2$O exchangeable). Anal. Calcd. for C$_{24}$H$_{20}$N$_6$O$_3$S$_2$ (504.58): C, 57.13; H, 4.00; N, 16.66. Found: C, 56.89; H, 3.76; N, 16.34.

5- Benzyl-3-methyl-8-{[2-(4-chlorophenylamino)-2-oxoethyl]sulfanyl}-4-oxo-4,5-dihydrothieno [*3,2-e*][1,2,4]triazolo[*4,3-a*]pyrimidine-2-carboxamide (7b)

M.P. 244-6 °C; Yield 68%; IR (KBr, cm^{-1}): 3491, 3365 (NH$_2$), 3297 (NH), 1689, 1650 (C=O), 1587 (C=N), 1267, 1092 (C-S-C). ^{1}H-NMR (δ ppm): 2.71 (s, 3H, CH$_3$), 3.91 (s, 2H, SCH$_2$), 5.29 (s, 2H, N-CH$_2$), 7.25-7.43 (m, 9H, phenyl-H and 4-chlorophenyl-H), 7.79 (s, 2H, NH$_2$, D$_2$O exchangeable), 10.30 (s, 1H, NH, D$_2$O exchangeable). Anal. Calcd. for C$_{24}$H$_{19}$ClN$_6$O$_3$S$_2$ (539.03): C, 53.48; H, 3.55; N, 15.59. Found: C, 53.19; H, 3.76; N, 15.24.

5- Benzyl-3-methyl-8-{[2-(4-methylphenylamino)-2-oxoethyl]sulfanyl}-4-oxo-4,5-dihydrothieno [*3,2-e*][1,2,4]triazolo[*4,3-a*]pyrimidine-2-carboxamide (7c)

M.P. 288-90 °C; Yield 69%; IR (KBr, cm^{-1}): 3382, 3364 (NH$_2$), 1686, 1644 (C=O), 1598 (C=N), 1252, 1062 (C-S-C). ^{1}H-NMR (δ ppm): 2.23 (s, 3H, 4-CH$_3$C$_6$H$_4$), 2.74 (s, 3H, CH$_3$), 3.93 (s, 2H, S-CH$_2$), 5.33 (s, 2H, N-CH$_2$), 7.06 (d, J = 6.9 Hz, 2H, 4-methylphenyl-C$_{3,5}$-H), 7.28-7.35 (m, 5H, phenyl-H), 7.42 (d, J =6.9 Hz, 2H, 4-methylphenyl-C$_{2,6}$-H), 7.79 (s, 2H, NH$_2$, D$_2$O exchangeable), 9.94 (s, 1H, NH, D$_2$O exchangeable). Anal. Calcd. for C$_{25}$H$_{22}$N$_6$O$_3$S$_2$ (518.61): C, 57.90; H, 4.28; N, 16.20. Found: C, 57.98; H, 4.35; N, 16.32.

5- Benzyl-3-methyl-8-{[2-(4-methoxyphenylamino)-2-oxoethyl]sulfanyl}-4-oxo-4,5-dihydrothieno [*3,2-e*][1,2,4]triazolo[*4,3-a*]pyrimidine-2-carboxamide (7d)

M.P. 255-7 °C; Yield 69%; IR (KBr, cm^{-1}): 3375, 3298 (NH$_2$), 3266 (NH), 1684, 1651 (C=O), 1597, 1552 (C=N), 1247, 1073 (C-S-C). ^{1}H-NMR (δ ppm): 2.85 (s, 3H, CH$_3$), 3.67 (s, 3H, OCH$_3$), 3.87 (s, 2H, S-CH$_2$), 5.29 (s, 2H, N-CH$_2$), 6.79 (d, J =7.65 Hz, 2H, 4-methoxyphenyl-C$_{2,6}$-H), 7.25-7.30 (m, 5H, phenyl-H), 7.38 (d, J =7.65 Hz, 2H, 4-methoxyphenyl-C$_{3,5}$-H),7.78 (s, 2H, NH$_2$, D$_2$O exchangeable), 9.87 (s, 1H, NH, D$_2$O exchangeable). Anal. Calcd. for C$_{25}$H$_{22}$N$_6$O$_4$S$_2$.1/2 H$_2$O (543.61): C, 55.19; H, 4.23; N, 15.45. Found: C, 55.25; H, 4.23; N, 15.48.

5- Benzyl-3-methyl-8-{[2-(4-acetylphenylamino)-2-oxoethyl]sulfanyl}-4-oxo-4,5-dihydrothieno [*3,2-e*][1,2,4]triazolo[*4,3-a*]pyrimidine-2-carboxamide (7e)

M.P. 250-2 °C; Yield 67%; IR (KBr, cm^{-1}): 3336, 3173 (NH$_2$), 1675 (C=O), 1594, 1538 (C=N), 1271, 1121 (C-S-C). ^{1}H-NMR (δ ppm): 2.51 (s, 3H, COCH$_3$), 2.74 (s, 3H, CH$_3$), 3.99 (s, 2H, S-CH$_2$), 5.33 (s, 2H, N-CH$_2$), 7.31-7.44 (m, 5H, phenyl-H), 7.55 (d, J = 8.7 Hz, 2H, 4-acetylphenyl-C$_{3,5}$-H), 7.79 (s, 2H, NH$_2$, D$_2$O exchangeable), 7.87 (d, J =8.7 Hz, 2H, 4-acetylphenyl-C$_{2,6}$-H), 10.38 (s, 1H, NH, D$_2$O exchangeable). Anal. Calcd. for C$_{26}$H$_{22}$N$_6$O$_4$S$_2$ (546.62): C, 57.13; H, 4.06; N, 15.37. Found: C, 57.17; H, 4.11; N, 15.45.

5- Benzyl-3-methyl-8-{[2-(4-methoxyphenyl)ethylamino)-2-oxoethyl]sulfanyl}-4-oxo-4,5-dihydrothieno[*3,2-e*][1,2,4]triazolo[*4,3-a*]pyrimidine-2-carboxamide (7f)

M.P. 210-2 °C; Yield 67%; IR (KBr, cm^{-1}): 3382, 3332 (NH$_2$), 1686 (C=O), 1594 (C=N), 1252, 1062 (C-S-C). ^{1}H-NMR (δ ppm): 2.54 (t, J = 7.8 Hz , 2H, $\underline{CH_2}$CH$_2$NH), 2.75 (s, 3H, CH$_3$), 3.15 (q, J = 7.8 Hz, 2H, CH$_2$$\underline{CH_2}$NH), 3.70 (s, 3H, OCH$_3$), 3.73 (s, 2H, S-CH$_2$), 5.33 (s, 2H, N-CH$_2$), 6.82 (d, J = 8.7 Hz, 2H, 4-methoxyphenyl-C$_{3,5}$-H), 7.06 (d, J =8.7 Hz, 2H, 4-methoxyphenyl-C$_{2,6}$-H), 7.26-7.43 (m, 5H, phenyl-H), 7.83 (s, 2H, NH$_2$, D$_2$O exchangeable), 8.16 (t, J = 5.7 Hz, 1H, NH, D$_2$O exchangeable). ^{13}C-NMR (d ppm): 14.25 (CH$_3$), 33.95 ($\underline{CH_2}$CH$_2$NH), 40.27 (SCH$_2$), 40.76 (CH$_2$$\underline{CH_2}$NH), 45.09 (CH$_2$-benzyl), 54.92 (OCH$_3$), 113.68 (methoxyphenyl-C$_3$ and C$_5$), 118.29 (benzyl-C$_4$), 127.49 (thienotriazolopyrimidine-C$_2$), 127.85 (benzyl-C$_2$ and C$_6$), 128.30 (benzyl-C$_3$ and C$_5$), 129.27 (thienotriazolopyrimidine-C$_3$), 129.43 (methoxyphenyl-C$_2$ and C$_6$), 130.96 (methoxyphenyl-C$_1$), 135.79 (thienotriazolopyrimidine-C$_{3a}$), 136.58 (thienotriazolopyrimidine-C$_{8a}$), 141.25 (thienotriazolopyrimidine-C$_8$), 141.88 (benzyl-C$_1$), 149.40 (thienotriazolopyrimidine-C$_{5a}$), 156.01 (methoxy-C$_4$), 157.61 (thienotriazolopyrimidine-C$_4$-C=O), 163.05 (CONH$_2$), 166.19 (CONH).Anal. Calcd. for C$_{27}$H$_{26}$N$_6$O$_4$S$_2$ (562.66): C, 57.63; H, 4.66; N, 14.94. Found: C, 57.34; H, 4.47; N, 14.71.

5- Benzyl-3-methyl-8-{[2-(substituted amino)-2-oxoethyl]sulfonyl}-4-oxo-4,5-dihydrothieno[*3,2-e*][1,2,4]triazolo[*4,3-a*]pyrimidine-2-carboxamides (8a-f)

An aqueous solution of 4% potassium permanganate was added dropwise to a stirred solution of the appropriate **7a-f** (0.5 mmol) in a mixture of glacial acetic acid and DMF (5 ml, 3:2). The addition of potassium permanganate solution was continued until the purple color persisted for 30 minutes. Stirring was maintained at room temperature for further 2 hours. The reaction mixture was left overnight, then cooled to 5 °C and saturated sodium sulfite solution was gradually added with stirring until the brown color disappeared. The white precipitate formed was filtered, washed with water, air dried and crystallized from DMF.

5- Benzyl-3-methyl-8-{[2-(phenylamino)-2-oxoethyl]sulfonyl}-4-oxo-4,5-dihydrothieno[*3,2-e*][1,2,4]triazolo[*4,3-a*]pyrimidine-2-carboxamide (8a)

M.P. 268-70 °C; Yield 64%; IR (KBr, cm^{-1}): 3410, 3300 (NH$_2$), 3252 (NH), 1684 (C=O), 1588 (C=N), 1317, 1157

(SO$_2$), 1217, 1092 (C-S-C). ^{1}H-NMR (δ ppm): 2.75 (s, 3H, CH$_3$), 3.95 (s, 2H, SO$_2$-CH$_2$), 5.33 (s, 2H, N-CH$_2$), 7.04-7.43 (m, 10H, 2 phenyl-H), 7.80 (s, 2H, NH$_2$, D$_2$O exchangeable), 10.03 (s, 1H, NH, D$_2$O exchangeable). Anal. Calcd. for C$_{24}$H$_{20}$N$_6$O$_5$S$_2$ (536.58): C, 53.72; H, 3.76; N, 15.66. Found: C, 53.59; H, 3.73; N 15.24.

5- Benzyl-3-methyl-8-{[2-(4-chlorophenylamino)-2-oxoethyl]sulfonyl}-4-oxo-4,5-dihydrothieno [3,2-e] [1,2,4]triazolo[4,3-a]pyrimidine-2-carboxamide (8b)

M.P. 260-2 $^\circ$C; Yield 65%; IR (KBr, cm^{-1}): 3420, 3300 (NH$_2$), 3252 (NH), 1686 (C=O), 1588 (C=N), 1318, 1144 (SO$_2$), 1216, 1092 (C-S-C). ^{1}H-NMR (δ ppm): 2.74 (s, 3H, CH$_3$), 3.94 (s, 2H, SO$_2$-CH$_2$), 5.33 (s, 2H, N-CH$_2$), 7.23-7.45 (m, 9H, phenyl-H and 4-chlorophenyl-H), 7.81 (s, 2H, NH$_2$, D$_2$O exchangeable), 10.17 (s, 1H, NH, D$_2$O exchangeable). ^{13}C-NMR (d ppm): 14.35 (CH$_3$), 45.39 (CH$_2$-benzyl), 53.67 (SO$_2$CH$_2$), 114.02 (chlorophenyl-C$_2$ and C$_6$), 118.09 (benzyl-C$_4$), 127.69(thienotriazolopyrimidine-C$_2$), 128.31 (benzyl-C$_2$ and C$_6$), 128.61 (benzyl-C$_3$ and C$_5$), 129.69 (chlorophenyl-C$_3$ and C$_5$), 130.05 (chlorophenyl-C$_4$), 130.56 (thienotriazolopyrimidine-C$_3$), 135.56 (thienotriazolopyrimidine-C$_{3a}$), 137.04 (thienotriazolopyrimidine-C$_{8a}$), 140.23 (chlorophenyl-C$_1$), 140.94 (thienotriazolopyrimidine-C$_8$), 141.97 (benzyl-C$_1$), 149.55 (thienotriazolopyrimidine-C$_{5a}$), 157.61 (thienotriazolopyrimidine-C$_4$-C=O), 163.05 (CONH$_2$), 166.19 (CONH). Anal. Calcd. for C$_{24}$H$_{19}$ClN$_6$O$_5$S$_2$ (571.03): C,50.48; H, 3.35; N 14.72. Found: C, 50.19; H, 3.12; N, 14.44.

5- Benzyl-3-methyl-8-{[2-(4-methylphenylamino)-2-oxoethyl]sulfonyl}-4-oxo-4,5-dihydrothieno [3,2-e] [1,2,4]triazolo[4,3-a]pyrimidine-2-carboxamide (8c)

M.P. 272-4 $^\circ$C; Yield 69%; IR (KBr, cm^{-1}): 3316, 3220 (NH$_2$), 3260 (NH), 1668, 1655 (C=O), 1592, 1559 (C=N), 1318, 1145 (SO$_2$), 1258, 1076 (C-S-C). ^{1}H-NMR (δ ppm): 2.20 (s, 3H, p-tolyl-CH$_3$), 2.70 (s, 3H, CH$_3$), 3.88 (s, 2H, SO$_2$-CH$_2$), 5.29 (s, 2H, N-CH$_2$), 7.02 (d, J = 7.6 Hz, 2H, 4-tolyl-C$_{3,5}$-H), 7.25-7.39 (m, 7H, phenyl-H and 4-tolyl-C$_{2,6}$-H), 7.78 (s, 2H, NH$_2$, D$_2$O exchangeable), 9.92 (s, 1H, NH, D$_2$O exchangeable). Anal. Calcd. for C$_{25}$H$_{22}$N$_6$O$_5$S$_2$ (550.61): C, 54.53; H, 4.03; N 15.26. Found: C, 54.29; H, 3.96; N, 15.14.

5- Benzyl-3-methyl-8-{[2-(4-methoxyphenylamino)-2-oxoethyl]sulfonyl}-4-oxo-4,5-dihydrothieno [3,2-e] [1,2,4]triazolo[4,3-a]pyrimidine-2-carboxamide (8d)

M.P. 265-7 $^\circ$C; Yield 63%; IR (KBr, cm^{-1}): 3312, 3217 (NH$_2$), 3264 (NH), 1678, 1655 (C=O), 1592, 1559 (C=N), 1318, 1173 (SO$_2$), 1248, 1076 (C-S-C). ^{1}H-NMR (δ ppm): 2.75 (s, 3H, CH$_3$), 3.71 (s, 3H, OCH$_3$), 3.91 (s, 2H, SO$_2$-CH$_2$), 5.33 (s, 2H, N-CH$_2$), 6.83 (d, J =8.7 Hz, 2H, 4-methoxyphenyl-C$_{2,6}$-H), 7.30-7.44 (m, 7H, phenyl-H and 4-methoxyphenyl-C$_{3,5}$-H), 7.80 (s, 2H, NH$_2$, D$_2$O exchangeable), 9.90 (s, 1H, NH, D$_2$O exchangeable). ^{13}C-NMR (d ppm): 14.26 (CH$_3$), 45.19 (CH$_2$-benzyl), 52.27 (SO$_2$CH$_2$), 55.92 (OCH$_3$), 114.27 (methoxyphenyl-C$_3$ and C$_5$), 118.69 (benzyl-C$_4$), 127.49 (thienotriazolopyrimidine-C$_2$), 127.71 (benzyl-C$_2$ and C$_6$), 128.29 (benzyl-C$_3$ and C$_5$), 129.47 (thienotriazolopyrimidine-C$_3$), 129.79 (methoxyphenyl-C$_2$ and C$_6$), 131.09 (methoxyphenyl-C$_1$), 135.60 (thienotriazolopyrimidine-C$_{3a}$), 137.54 (thienotriazolopyrimidine-C$_{8a}$),

141.31 (thienotriazolopyrimidine-C$_8$), 141.68 (benzyl-C$_1$), 149.77 (thienotriazolopyrimidine-C$_{5a}$), 155.95 (methoxy-C$_4$), 157.81 (thienotriazolopyrimidine-C$_4$-C=O), 162.05 (CO-NH$_2$), 165.19 (CONH). MS, m/z (relative abundance %): 566 [M$^+$, (63.87)], 488 (77.31), 478 (65.55), 443 (65.55), 395 (68.91), 380 (68.07), 379 (82.35), 361 (72.27), 352 (70.59), 344 (68.07), 331 (72.27), 313 (78.99), 254 (68.91), 142 (66.39), 119 (79.83), 105 (100), 99 (66.39), 91 (94.96), 69 (72.27). Anal. Calcd. for C$_{25}$H$_{22}$N$_6$O$_6$S$_2$ (566.61): C, 52.99; H, 3.91; N, 14.83. Found: C, 52.99; H, 4.25; N, 14.92.

5- Benzyl-3-methyl-8-{[2-(4-acetylphenylamino)-2-oxoethyl]sulfonyl}-4-oxo-4,5-dihydrothieno [3,2-e] [1,2,4]triazolo[4,3-a]pyrimidine-2-carboxamide (8e)

M.P. 270-2 $^\circ$C; Yield 63%; IR (KBr, cm^{-1}): 3335, 3174 (NH$_2$), 3264 (NH), 1674 (C=O), 1594 (C=N), 1359, 1176 (SO$_2$), 1271, 1079 (C-S-C). ^{1}H-NMR 2.35 (s, 3H, COCH$_3$), 2.70 (s, 3H, CH$_3$), 3.95 (s, 2H, SO$_2$-CH$_2$), 5.29 (s, 2H, N-CH$_2$), 7.29-7.83 (m, 9H, phenyl-H and 4-acetylphenyl-H), 7.96 (s, 2H, NH$_2$, D$_2$O exchangeable), 10.48 (s, 1H, NH, D$_2$O exchangeable). MS, m/z (relative abundance %): 578 [M$^+$, (49.45)], 566 (47.25), 373 (47.25), 353 (48.90), 319 (47.80), 306 (51.65), 243 (47.25), 273 (50.55), 235 (45.05), 187 (49.45), 145 (51.65), 135 (46.15), 122 (45.05), 120 (45.05), 118 (56.04), 91 (47.25), 77 (74.18), 60 (100). Anal. Calcd. for C$_{26}$H$_{22}$N$_6$O$_6$S$_2$ (578.62): C, 53.97; H, 3.83; N, 14.52. Found: C, 53.89; H, 3.76; N, 14.14.

5- Benzyl-3-methyl-8-{[2-(4-methoxyphenyl)ethylamino)-2-oxoethyl]sulfonyl}-4-oxo-4,5-dihydrothieno[3,2-e] [1,2,4]triazolo[4,3-a]pyrimidine-2-carboxamide (8f)

M.P. 280-2 $^\circ$C; Yield 61%; IR (KBr) ν_{max} (cm^{-1}): 3330, 3190 (NH$_2$), 3274 (NH), 1684 (C=O), 1594 (C=N), 1319, 1145 (SO$_2$), 1261, 1080 (C-S-C). ^{1}H-NMR (DMSO-d6): δ (ppm) 2.53 (t, J = 7.8 Hz , 2H, $\underline{CH_2}$CH$_2$NH), 2.74 (s, 3H, CH$_3$), 3.13 (q, J = 7.8 Hz, 2H, CH$_2\underline{CH_2}$NH), 3.72 (s, 3H, OCH$_3$), 3.79 (s, 2H, SO$_2$-CH$_2$), 5.36 (s, 2H, N-CH$_2$), 6.93 (d, J = 8.7 Hz, 2H, 4-methoxyphenyl-C$_{3,5}$-H), 7.15 (d, J =8.7 Hz, 2H, 4-methoxyphenyl-C$_{2,6}$-H), 7.24-7.44 (m, 5H, phenyl-H), 7.84 (s, 2H, NH$_2$, D$_2$O exchangeable), 8.27 (t, J = 6.7 Hz, 1H, NH, D$_2$O exchangeable). Anal. Calcd. (%) for C$_{27}$H$_{26}$N$_6$O$_6$S$_2$: C, 54.53; H, 4.41; N, 14.13. Found: C, 54.29; H, 4.15; N, 14.14.

5- Benzyl-3-methyl-8-(substituted sulfanyl)-4-oxo-4,5-dihydrothieno[3,2-e][1,2,4]triazolo[4,3-a] pyrimidine-2-carboxamides (9a-c)

A mixture of **5** (0.37 g, 1 mmol) , appropriate alkyl or aralkyl halide 1 (1 mmol) and anhydrous potassium carbonate (0.14 g, 1 mmol) in dry acetone (20 ml) was stirred and refluxed for 5 hours. The mixture was then cooled, poured into ice-cold water, filtered and the solid obtained was dried and crystallized from DMF.

5-Benzyl-3-methyl-8-(methylsulfanyl)-4-oxo-4,5-dihydrothieno[3,2-e][1,2,4]triazolo[4,3-a] pyrimidine-2-carboxamide (9a)

M.P. 280-2 $^\circ$C; Yield 75%; IR (KBr, cm^{-1}): 3329, 3149 (NH$_2$, NH), 1677 (C=O), 1593, 1541 (C=N), 1288, 1029 (C-

S-C). ^{1}H-NMR (δ ppm): 2.61 (s, 3H, CH$_3$), 2.71 (s, 3H, S-CH$_3$), 5.28 (s, 2H, N-CH$_2$), 7.22-7.40 (m, 5H, phenyl-H), 7.77 (s, 2H, NH$_2$, D$_2$O exchangeable). Anal. Calcd. for C$_{17}$H$_{15}$N$_5$O$_2$S$_2$ (385.46): C, 52.97; H, 3.92; N, 18.17. Found: C, 53.04; H, 3.89; N, 18.31.

5-Benzyl-3-methyl-8-(ethylsulfanyl)-4-oxo-4,5-dihydrothieno[*3,2-e*][1,2,4]triazolo[*4,3-a*] pyrimidine-2-carboxamide (9b)

M.P. 285-7 °C; Yield 74%; IR (KBr, cm[-1]): 3329, 3156 (NH$_2$, NH), 1680 (C=O), 1586, 1540 (C=N), 1268, 1060 (C-S-C). ^{1}H-NMR (δ ppm): 1.29 (t, J = 7.2 Hz , 3H, SCH$_2$CH$_3$), 2.74 (s, 3H, CH$_3$), 3.09 (q, J = 7.2 Hz, 2H, SCH$_2$CH$_3$), 5.32 (s, 2H, N-CH$_2$), 7.26-7.44 (m, 5H, phenyl-H), 7.77 (s, 2H, NH$_2$, D$_2$O exchangeable). ^{13}C-NMR (d ppm): 14.26 (CH$_3$), 14.97 (SCH$_2$CH$_3$), 43.45 (SCH$_2$CH$_3$), 45.09 (CH$_2$-benzyl), 118.50 (benzyl-C$_4$), 127.49 (thienotriazolopyrimidine-C$_2$), 127.82 (benzyl-C$_2$ and C$_6$), 128.29 (benzyl-C$_3$ and C$_5$), 128.97 (thienotriazolopyrimidine-C$_3$),135.92(thienotriazolopyrimidine-C$_{3a}$), 136.83 (thienotriazolopyrimidine-C$_{8a}$), 140.94 (thienotriazolopyrimidine-C$_8$), 141.56 (benzyl-C$_1$), 149.58 (thienotriazolopyrimidine-C$_{5a}$), 156.18 (thienotriazolopyrimidine-C$_4$-C=O), 163.11 (CONH$_2$). Anal. Calcd. for C$_{18}$H$_{17}$N$_5$O$_2$S$_2$ (399.49): C, 54.12; H, 4.29; N, 17.53. Found: C, 54.21; H, 4.34; N, 17.64.

5-Benzyl-3-methyl-8-(benzylsulfanyl)-4-oxo-4,5-dihydrothieno[*3,2-e*][1,2,4]triazolo[*4,3-a*] pyrimidine-2-carboxamide (9c)

M.P. 244-6 °C; Yield 77%; IR (KBr, cm[-1]): 3319, 3143 (NH$_2$, NH), 1682 (C=O), 1586, 1550 (C=N), 1258, 1062 (C-S-C). ^{1}H-NMR (δ ppm): 2.73 (s, 3H, CH$_3$), 4.35 (s, 2H, S-CH$_2$), 5.32 (s, 2H, N-CH$_2$), 7.21-7.42 (m, 10H, 2 phenyl-H), 7.79 (s, 2H, NH$_2$, D$_2$O exchangeable). Anal. Calcd. for C$_{23}$H$_{19}$N$_5$O$_2$S$_2$ (461.56): C, 59.85; H, 4.15; N, 15.17. Found: 59.91; H, 4.17; N, 15.26.

5-Benzyl-3-methyl-8-(substituted sulfonyl)-4-oxo-4,5-dihydrothieno[*3,2-e*][1,2,4]triazolo[*4,3-a*] pyrimidine-2-carboxamides (10a-c)

An aqueous solution of 4% potassium permanganate was added dropwise to a stirred solution of the appropriate **9a-c** (5 mmol) in glacial acetic acid (5 ml). The addition of potassium permanganate solution was continued until the purple color persisted for 30 minutes. Stirring was maintained at room temperature for further 2 hours. The reaction mixture was left overnight, then cooled to 5 °C , saturated sodium sulfite solution was gradually added with stirring until the brown color disappeared. The white precipitate formed was filtered, washed with water, air dried and crystallized from DMF.

5-Benzyl-3-methyl-8-(methylsulfonyl)-4-oxo-4,5-dihydrothieno[*3,2-e*][1,2,4]triazolo[*4,3-a*] pyrimidine-2-carboxamide (10a)

M.P. >300 °C; Yield 68%; IR (KBr, cm[-1]): 3374, 3183 (NH$_2$), 3270 (NH), 1681, 1640 (C=O), 1591 (C=N), 1342, 1146 (SO$_2$), 1277, 1074 (C-S-C). ^{1}H-NMR (δ ppm): 2.74 (s,

3H, CH$_3$), 3.68 (s, 3H, SO$_2$CH$_3$), 5.40 (s, 2H, N-CH$_2$), 7.27-7.47 (m, 5H, phenyl-H), 7.87 (s, 2H, NH$_2$, D$_2$O exchangeable. Anal. Calcd. for C$_{17}$H$_{15}$N$_5$O$_4$S$_2$ (417.46): C, 48.91; H, 3.62; N, 16.78. Found: C, 48.89; H, 3.36; N, 16.44.

5-Benzyl-3-methyl-8-(ethylsulfonyl)-4-oxo-4,5-dihydrothieno[*3,2-e*][1,2,4]triazolo[*4,3-a*] pyrimidine-2-carboxamide (10b)

M.P. > 300 °C; Yield 62%; IR (KBr, cm[-1]): 3341, 3171 (NH$_2$, NH), 1681 (C=O), 1586 (C=N), 1336, 1145 (SO$_2$), 1272, 1076 (C-S-C). ^{1}H-NMR (δ ppm): 2.29 (t, J = 7.6 Hz , 3H, SO$_2$CH$_2$CH$_3$), 2.75 (s, 3H, CH$_3$), 3.98 (q, J = 7.6 Hz, 2H, SO$_2$CH$_2$CH$_3$), 5.40 (s, 2H, N-CH$_2$), 7.26-7.37 (m, 5H, phenyl-H), 7.89 (s, 2H, NH$_2$, D$_2$O exchangeable). ^{13}C-NMR (d ppm): 14.27(CH$_3$), 14.80 (SO$_2$CH$_2$CH$_3$), 29.95 (SO$_2$CH$_2$CH$_3$), 45.09 (CH$_2$-benzyl), 118.40 (benzyl-C$_4$), 127.38 (thienotriazolopyrimidine-C$_2$), 127.81 (benzyl-C$_2$ and C$_6$), 128.26 (benzyl-C$_3$ and C$_5$), 128.87 (thienotriazolopyrimidine-C$_3$), 135.82 (thienotriazolopyrimidine-C$_{3a}$), 136.73 (thienotriazolopyrimidine-C$_{8a}$), 140.84 (thienotriazolopyrimidine-C$_8$), 141.46 (benzyl-C$_1$), 149.48 (thienotriazolopyrimidine-C$_{5a}$), 156.08 (thienotriazolopyrimidine-C$_4$-C=O), 163.01 (CONH$_2$). Anal. Calcd. for C$_{18}$H$_{17}$N$_5$O$_4$S$_2$ (431.49): C, 50.10; H, 3.97; N, 16.23. Found: C, 49.89; H, 3.76; N, 16.14.

5-Benzyl-3-methyl-8-(benzylsulfonyl)-4-oxo-4,5-dihydrothieno[*3,2-e*][1,2,4]triazolo[*4,3-a*] pyrimidine-2-carboxamide (10c)

. M.P. 280-2 °C; Yield 67%; IR (KBr, cm[-1]): 3376, 3165 (NH$_2$), 3245 (NH), 1684, 1640 (C=O), 1594 (C=N), 1332, 1144 (SO$_2$), 1275, 1076 (C-S-C). ^{1}H-NMR 2.74 (s, 3H, CH$_3$), 4.46 (s, 2H, SO$_2$CH$_2$), 5.41 (s, 2H, N-CH$_2$), 7.23-7.44 (m, 10H, 2 phenyl-H), 7.88 (s, 2H, NH$_2$, D$_2$O exchangeable). MS, m/z (relative abundance %): 493 [M$^+$, (5.43)], 428 (22.22), 426 (20.93), 404 (27.13), 374 (23.77), 370 (24.55), 268 (22.22), 251 (23.00), 230 (20.93), 191 (23.00), 172 (22.48), 137(21.19), 91(100), 83 (26.61).Anal. Calcd. for C$_{23}$H$_{19}$N$_5$O$_4$S$_2$ (493.56): C, 55.97; H, 3.88; N, 14.19. Found: C, 55.89; H, 3.76; N, 14.04.

5-Benzyl-3-methyl-8-substituted-4-oxo-4,5-dihydrothieno[*3,2-e*][1,2,4] triazolo[*4,3-a*]pyrimidine-2-carboxamides (11a-c)

A mixture of **9a** (1.16 g, 3 mmol) and the selected amine (9 mmol) was heated in an oil bath at 160–170 °C for 6 h. The reaction mixture was triturated with dilute hydrochloric acid, filtered, washed with water, dried, and crystallized from DMF.

5-Benzyl-3-methyl-8-morpholino-4-oxo-4,5-dihydrothieno[*3,2-e*][1,2,4]triazolo[*4,3-a*]pyrimidine-2-carboxamide (11a)

M.P. 246-8 °C; Yield 66%; IR (KBr, cm[-1]): 3357, 3156 (NH$_2$), 1689, 1642 (C=O), 1602 (C=N), 1164, 1075 (C-S-C). ^{1}H-NMR (δ ppm): 2.06-2.69 (m, 11H, CH$_3$ and morpholine-H), 5.29 (s, 2H, N-CH$_2$), 7.20-7.29 (m, 5H, phenyl-H), 7.59 (s, 2H, NH$_2$, D$_2$O exchangeable). ^{13}C-NMR (d ppm): 14.19

(CH$_3$), 14.73 (morpholin-C$_3$ and C$_5$), 46.74 (CH$_2$-benzyl), 54.30 (morpholin-C$_2$ and C$_6$), 118.93 (benzyl-C$_4$), 126.68 (thienotriazolopyrimidine-C$_2$), 127.40 (benzyl-C$_2$ and C$_6$), 128.43 (benzyl-C$_3$ and C$_5$), 128.97 (thienotriazolopyrimidi-ne-C$_3$), 135.24 (thienotriazolopyrimidine-C$_{3a}$), 137.17 (thie-notriazolopyrimidine-C$_{8a}$), 140.94 (thienotriazolopyrimidine-C$_8$), 141.56 (benzyl-C$_1$), 149.58 (thienotriazolopyrimidine-C$_{5a}$), 158.44 (thienotriazolopyrimidine-C$_4$-C=O), 163.10 (CONH$_2$). Anal. Calcd. for C$_{20}$H$_{20}$N$_6$O$_3$S (424.48): C, 56.59; H, 4.75; N, 19.80. Found: C, 56.72; H, 4.74; N, 19.97.

5-Benzyl-3-methyl-8-piperidino-4-oxo-4,5-dihydrothieno[*3,2-e*][1,2,4] triazolo[*4,3-a*]pyrimidine-2-carboxamide (11b)

M.P. 255-7 °C; Yield 65%; IR (KBr, cm^{-1}): 3358, 3166 (NH$_2$), 1679, 1653 (C=O), 1604 (C=N), 1174, 1021 (C-S-C). ^{1}H-NMR (δ ppm): 2.50-2.89 (m, 13H, CH$_3$ and piperidine-H), 5.30 (s, 2H, N-CH$_2$), 7.22-7.36 (m, 5H, phenyl-H), 7.60 (s, 2H, NH$_2$, D$_2$O exchangeable). Anal. Calcd. for C$_{21}$H$_{22}$N$_6$O$_2$S (422.50): C, 59.70; H, 5.25; N, 19.89. Found: C, 59.59; H, 5.16; N, 19.74.

5-Benzyl-3-methyl-8-(N-phenylpiperazino)-4-oxo-4,5-dihydrothieno[*3,2-e*][1,2,4] triazolo[*4,3-a*] pyrimidine-2-carboxamide (11c)

M.P. 251-3 °C; Yield 62%; IR (KBr, cm^{-1}): 3358, 3166 (NH$_2$), 1689, 1642 (C=O), 1602 (C=N), 1164, 1026 (C-S-C). ^{1}H-NMR (δ ppm): 2.50-2.89 (m, 11H, CH$_3$ and piperazine-H), 5.30 (s, 2H, N-CH$_2$), 7.22-7.36 (m, 10H, 2 phenyl-H), 7.60 (s, 2H, NH$_2$, D$_2$O exchangeable). Anal. Calcd. for C$_{26}$H$_{25}$N$_7$O$_2$S (499.59): C, 62.51; H, 5.04; N, 19.63. Found: C, 62.39; H, 4.79; N, 19.34.

BIOLOGICAL EVALUATION

Anti-Inflammatory (AI) Activity

Formalin-Induced Paw Edema Bioassay (Acute Inflammatory Model)

Male albino rats weighing 180–200 g were used throughout the assay [19]. They were kept in the animal house under standard condition of light and temperature with free access to food and water. The animals were randomly divided into groups each of five rats. One group of five rats was kept as a control and another group received the standard drug diclofenac Na (at a dose of 20 mg/kg body weight po). A solution of formalin (2%, 0.1 mL) was injected into the subplanter region of the left hind paw under light ether anesthesia 1h after oral administration (po) of the test compound (at a dose level of 20 mg/kg body weight). The paw volume (mL) was measured by means of water plethysmometer and re-measured again 1, 2 and 4 h after administration of formalin. The edema was expressed as an increase in the volume of paw, and the percentage of edema inhibition for each rat and each group was obtained as follows:

% Inhibition = (Vt–Vo) control–(Vt–Vo) tested compound / (Vt–Vo) control ×100

Where Vt = volume of edema at specific time interval and Vo = volume of edema at zero time interval.

Formalin-Induced Paw Edema Bioassay (Sub-Acute Inflammatory Model)

Rats in the first experiment were given the same test compounds at a dose level of 20 mg/kg body weight daily for 7 consecutive days. A solution of formalin (2%, 0.1 mL) was injected into the subplanter region of the left hind paw under light ether anesthesia 1 h after oral administration (po) of the test compound. A second injection of formalin (2%, 0.1 mL) was given on the third day. The changes in the volume of paw were measured plethymographically at the first and eighth days [19].

Ulcerogenic Activity

Male albino rats (180–200 g) were divided into groups each of five animals and were fasted for 12 h prior to the administration of the test compounds. Water was given ad libitum. Control group received 1% gum acacia orally. Other groups received diclofenac Na or the test compounds orally in two equal doses at 0 and 12 h for three successive days at a dose of 300 mg/kg per day. Animals were sacrificed by diethyl ether 6 h after the last dose and their stomachs were removed. An opening at the greater curvature was made and the stomach was cleaned by washing with cold saline and inspected with a 3×magnifying lens for any evidence of hyperemia, hemorrhage, definite hemorrhagic erosion or ulcer [20].

Acute Toxicity

Twelve groups of rats (180–200 g) each consists of five animals, were used in this test [21]. The animals were fasted for 24 h prior to administration of the test compounds. The compounds were given orally in graded doses of 0.1–0.3 g/kg body weight, po. The compounds were screened at graded doses for their acute lethal doses (ALD$_{50}$) and the mortalities were recorded at each dose level after 24 h.

Determination of Effective Dose 50 (ED$_{50}$)

The selected compounds were further tested at 5, 10, 20, 40, and 50 mg/Kg body weight and the ED$_{50}$ was determined by measuring the inhibition of the edema volume 2 h after formalin injection.

Statistical Analysis of Data

The data obtained are presented as means ± SE of the mean. The concentration- dependent effects of various drugs *in vitro* were evaluated statistically by the randomized block design analysis of Variance (ANOVA) followed by Student–Newman–Keuls Multiple Comparison Test. The difference in results was considered significant when $P < 0.05$.

Analgesic Activity

Analgesic activity was determined using tail withdrawal response to immersion of rat tail in water at 55 °C according to the procedure described by Janssen *et al.* [22]. Male albino rats weighing 120–150 g were used throughout this assay. They were kept in the animal house under standard condition of light and temperature with free access to food and water. The animals were randomly divided into groups

each of five rats. One group of five rats was kept as a control and another group received the standard drug diclofenac Na (at a dose of 20 mg/kg body weight po). The tested compounds were administrated orally at a dose of 20 mg/kg and diclofenac Na was used as a reference drug (20 mg/kg). The recorded values were the average of five administrations ± SE and the percentage increase of the reaction time (after 1–4 h time intervals) was calculated in comparison with the basal values.

Docking Studies

Computer simulated docking experiments were carried out under an MMFF94X force field in (PDB ID code: **1PXX**, Diclofenac Na bound in the active site) using chemical computing group's Molecular Operating Environment (MOE-Dock 2008) software, Montréal, Canada [23].

Crystal coordinates from the X-ray crystal structure of COX-2 were taken from the protein data bank (PDB ID code: **1PXX**). The ligand molecules were constructed using the builder module and were energy minimized using Force Field MMFF94x. The active site of COX-2 was generated using the MOE-Alpha Site Finder, and then ligands were docked within this active site using the MOE Dock. The lowest energy conformation was selected and the ligand interactions (hydrogen bonding and hydrophobic interaction) with COX-2 were determined.

RESULTS AND DISCUSSION

Chemistry

The synthetic pathway of the intermediate and final compounds are illustrated in Schemes **1** and **2**. According to Scheme1 The key intermediate 5-benzyl-3-methyl-4-oxo-8-thioxo-4,5,7,8-tetrahydrothieno[*3,2-e*][1,2,4]triazolo[*4,3-a*]pyrimidine-2-carboxamide **(5)** was prepared through a 4-step synthetic protocol in a good yield according to our reported procedures [17]. 2-chloro-N-substitutedacetamides **(6a-f)** were prepared by treating different amines with chloroacetyl chloride in methylene chloride and anhydrous K_2CO_3, following Baraldi's procedure [24] and was allowed to react with **(5)** in dry acetone and anhydrous K_2CO_3, to give compounds **(7a-f)**. ^{1}H NMR spectra showed a characteristic singlet at 3.73-3.99 ppm integrated for SCH_2 protons in addition to D_2O exchangeable singlet at 8.16-10.38 attributed to NH proton. Additionally, ^{13}C NMR spectrum for **(7f)** showed signals at 14.25, 40.27, 45.09, 141.25, 157.61, 163.05, 166.19 due to CH_3, SCH_2, CH_2-benzyl, thienotriazolopyrimidine-C_8, and the three C=O groups respectively providing a substantial proof for the assigned structure of **(7a-f)** compounds.

Oxidation of the thio function in compounds **(7a-f)** to the corresponding sulfone derivatives **(8a-f)** was accomplished using $KMnO_4$ in a mixture of glacial acetic acid and DMF utilizing a previously reported procedure [25]. Analytical and spectral data of compounds **(8a-f)** are in accordance with their structures. IR spectra of compounds **(8a-f)** revealed additional absorption bands at 1317-1359 and 1144-1176 cm^{-1} corresponding to the sulfonic group. The MS spectra of **(8d)** and **(8e)** showed a molecular ion peak at m/z 566 (63.87%) and 578 (49.45%) respectively that matches their

molecular formulae. Additionally, ^{13}C NMR spectra of compounds **(8b)** and **(8d)** revealed signals characteristic to CH_3, SO_2CH_2, CH_2-benzyl, thienotriazolopyrimidine- C_8, and the three C=O at their expected chemical shifts.

According to Scheme 2, reaction of **(5)** with different alkyl and aralkyl derivatives in dry acetone and anhydrous K_2CO_3, afforded the target S- alkyl and aralkylthio derivatives **(9a-c)** IR spectra of these compounds exhibited strong absorption bands at 3319-3329, 3143-3156 and 1677-1682 cm^{-1} due to NH_2, NH and C=O groups respectively. While their ^{1}H NMR spectra matched their proposed structures. ^{13}C NMR spectra of compound **(9b)** revealed signals at 14.26, 14.97, 43.45, 140.94, 156.18, 163.11 ppm due to CH_3, $SCH_2\underline{CH_3}$, $S\underline{CH_2}CH_3$, thienotriazolopyrimidine-C_8, and the two C=O respectively.

Synthesis of their corresponding sulfones **(10a-c)** was accomplished by oxidation of the alkyl or aralkyl thio derivatives **(9a-c)** using $KMnO_4$ in glacial acetic acid. The chemical structure of these compounds was confirmed by their IR, ^{1}H NMR, ^{13}C NMR and MS spectral data. The IR spectra revealed an additional absorption bands at 1332-1344 and 1142-1146 cm^{-1} due to SO_2 group, while their ^{1}H NMR and ^{13}C NMR spectra matched their proposed structures. Mass spectrum of **(10c)** showed a molecular ion peak at m/z 493 (5.43 %) which is in accordance with its molecular formula.

Moreover, fusion of the methylthio derivative **(9a)** with the appropriate aromatic amines in an oil bath at 160-170°C afforded the corresponding 8-amino derivatives **(11a-c)**. ^{1}H NMR showed the absence of the methylthio singlet and the appearance of the signals assigned to the morpholine, piperidine and piperazine protons as well as ^{13}C-NMR spectrum for compound **(11a)** showed signals at 14.19, 14.73, 54.30, 140.94, 158.44, 163.10 ppm due to CH_3, morpholine C_3 and C_5, morpholine C_2 and C_6, thienotriazolopyrimidine-C_8, and the two C=O respectively which provided further confirmation of the structure.

BIOLOGICAL EVALUATION

Anti-Inflammatory (AI) Activity

The AI activity of the designed compounds was evaluated by utilizing the formalin-induced paw edema bioassay [19] using diclofenac Na (20 mg/kg) as a reference standard anti-inflammatory agent. The paw edema was employed as a model for acute and sub-acute inflammation. The data obtained were presented in (Tables **1** and **2**) and expressed as means ± SE. Statistical differences of control and test groups was carried out using the Analysis of Variance (ANOVA) followed by 'Student–Newman–Keuls Multiple Comparison Test'. They were performed using computer package of the Statistical Analysis System (SAS, 1987), SAS Incorporation Institute. The difference in results was considered significant when $P < 0.05$.

Formalin-Induced Paw Edema Bioassay (Acute Inflammatory Model)

In this acute inflammatory model [19] each test compound was dosed orally (20 mg/kg body weight) 1 h prior to induction of inflammation by formalin injection. Diclofenac Na was utilized as a reference drug at a dose of

a, R = C₆H₅; b, R= 4-Cl-C₆H₄; c, R= 4-CH₃C₆H₄; d, R= 4-OCH₃-C₆H₄; e, R= 4-COCH₃C₆H₄; f, R= 4-OCH₃C₆H₄C₂H₄

Reagents and conditions: i) C₆H₅CH₂NCS / K₂CO₃/ acetonitrile / reflux ;
ii) CH₃I / K₂CO₃ / dry acetone / reflux ; iii) N₂H₄ 99 % / EtOH / reflux; iv)CS₂ / KOH/ EtOH / reflux
v) anhydrous K₂CO₃ / dry acetone / reflux; vi) KMnO₄ / gl. CH₃COOH/ DMF/ RT

Scheme 1. Synthesis of compounds **2-5,7a-f** and **8a-f.**

20 mg/kg, po. The anti-inflammatory activity was then calculated 1–4 h after induction and presented in (Table **1**) as the mean paw volume (mL) in addition to the percentage anti-inflammatory activity (AI%).

Comparative study of the anti-inflammatory activity of test compounds relative to the reference drug Diclofenac Na at different time intervals revealed the following:

After 1 h, eight compounds showed distinctive pharmacokinetic profiles as shown from their rapid onset of action which was higher than diclofenac Na at a dose of 20 mg/kg, po. A remarkable AI% was recorded for the thienotriazolopyrimidines **7f** (61%), **8a** (50%), **8e** (53%), **8f** (76%), **9a**

(53%), **9c** (53%), **10a** (69%) and **10c** (73%), when compared to diclofenac Na (42%), whereas, **7a**, **8b**, **8c**, **8d**, **10b** and **11c** showed AI% (42-46%) nearly equipotent to diclofenac Na. The other compounds showed moderate to weak activity. After 2 h interval, thienotriazolopyrimidines **7f, 8c, 10c, 11a** and **11c** displayed equipotent anti-inflammatory activity (41-45%), to diclofenac sodium (45%).

After 4 h time interval thienotriazolopyrimidines **11a** and **11c** were nearly effective in inhibiting the paw edema with percentage activity of 64 and 60% respectively compared to the reference drug (66%). while the 2-methylthienotriazolopyrimidine **8f** was found to be equipotent to diclofenac sodium, whereas, **7f, 8e, 10a** and **10c**

For 9 and 10: a, R = CH$_3$; b, R= C$_2$H$_5$; c, R= CH$_2$C$_6$H$_5$

11: a,, R'= morpholine; b, R'= piperidine; c, R'= N-phenylpiperazine

Reagents and conditions: i) anhydrous K$_2$CO$_3$/ dry acetone / reflux; ii) KMnO$_4$/ gl.CH$_3$COOH/ RT

iii) the appropriate amines / fusion at 160 - 170 ^{0}C

Scheme 2. Synthesis of compounds **9a-c, 10a-c** and **11a-c.**

displayed lower anti-inflammatory activity (50-52%). The other compounds showed weak activity.

The most active compounds (**7f, 8f**, **10a**, **10c**, **11a** and **11c**) were further tested at 5, 10, 20, 40 and 50 mg/kg body weight in order to determine their ED$_{50}$ values. All compounds were found to be nearly equipotent (ED$_{50}$ = 14.78 - 19.65 mg/kg, Table **1**) compared to the reference drug diclofenac sodium (ED$_{50}$ = 13.56 mg/kg). Results are illustrated by (Fig. **3**).

Formalin-Induced Paw Edema Bioassay (Sub-Acute Inflammatory Model)

For this sub-acute inflammatory model [19], inflammation was induced by formalin injection in the first and third days, and test compounds were administered once orally (at 20 mg/kg daily) for 7 days. Again, diclofenac sodium was used as a reference agent. The anti-inflammatory activity was calculated at 1st and 8th day after induction and presented in (Table **2**) as the mean paw volume and the percentage anti-inflammatory activity (AI%).

The obtained data revealed that, at 1st day, thienotriazolopyrimidines **10c** and **11c** displayed anti-inflammatory activity (57%) nearly equivalent to the reference drug diclofenac sodium (60%). Meanwhile, **7e** and **11a** displayed a reasonable anti-inflammatory activity (52 and 51%) respectively.

At the 8th day, compounds **8f, 10a, 10c** and **11c** were found to be nearly as effective (54 - 58%) as diclofenac sodium (56%). The other compounds displayed moderate to weak activity. Results are illustrated by (Fig. **4**).

A further interpretation of the anti-inflammatory activity of the test compounds in pre-mentioned screens (Tables **1**, **2**) revealed that thienotriazolopyrimidines **8f, 10a, 10c** and **11c** showed remarkable activity in both the acute and subacute inflammatory models. On the other hand, thienotriazolopyrimidines **7f, 8a, 8e, 9a** and **9c** displayed pronounced activity in the acute inflammatory model nevertheless they proved to be less active in the subacute inflammatory model. This fact would suggest that such type of compounds might be effective in managing acute inflammation, while they

Table 1.   **Anti-Inflammatory Activity (AI) of The newly Synthesized Compounds in Formalin-Induced Rat Paw Edema Bioassay (Acute Inflammatory Model)**

Compound[a]	Volume of edema (mL)[b]				ED_{50} (mg/Kg)
	0	**1 h**	**2 h**	**4 h**	
Control	0.30 ± 0.01	0.56 ± 0.02	0.61 ± 0.01	0.80 ± 0.02	
7a	0.36 ± 0.01	0.50 ± 0.02[c] (46)[d]	0.56 ± 0.02[c] (35)	0.64 ± 0.03[c] (44)	
7b	0.31 ± 0.01	0.54 ± 0.01[c] (11)	0.51 ± 0.01[c] (35)	0.67 ± 0.01[c] (28)	
7c	0.40 ± 0.03	0.56 ± 0.03[c] (38)	0.56 ± 0.03[c] (32)	0.70 ± 0.02[c] (30)	
7d	0.33 ± 0.02	0.56 ± 0.01[c] (11)	0.60 ± 0.02[c] (06)	0.69 ± 0.02[c] (28)	
7e	0.31 ± 0.03	0.49 ± 0.01[c] (30)	0.53 ± 0.01[c] (29)	0.65 ± 0.03[c] (52)	
7f	0.36 ± 0.01	0.46 ± 0.02[c] (61)	0.53 ± 0.01[c] (45)	0.60 ± 0.01[c] (52)	18.32
8a	0.33 ± 0.02	0.46 ± 0.03[c] (50)	0.52 ± 0.03[c] (38)	0.62 ± 0.02[c] (42)	
8b	0.31 ± 0.03	0.46 ± 0.01[c] (42)	0.51 ± 0.01[c] (35)	0.63 ± 0.03[c] (36)	
8c	0.35 ± 0.01	0.49 ± 0.01[c] (46)	0.58 ± 0.01[c] (41)	0.69 ± 0.01[c] (42)	
8d	0.34 ± 0.01	0.48 ± 0.02[c] (46)	0.54 ± 0.02[c] (35)	0.65 ± 0.01[c] (38)	
8e	0.37 ± 0.02	0.49 ± 0.01[c] (53)	0.57 ± 0.02[c] (35)	0.62 ± 0.01[c] (50)	
8f	0.33 ± 0.01	0.39 ± 0.01[c] (76)	0.52 ± 0.01[c] (38)	0.50 ± 0.03[c] (66)	14.78
9a	0.30 ± 0.02	0.42 ± 0.01[c] (53)	0.57 ± 0.03[c] (12)	0.61 ± 0.02[c] (38)	
9b	0.32 ± 0.02	0.52 ± 0.01[c] (23)	0.55 ± 0.03[c] (25)	0.62 ± 0.01[c] (40)	
9c	0.32 ± 0.02	0.44 ± 0.01[c] (53)	0.56 ± 0.01[c] (22)	0.63 ± 0.01[c] (38)	
10a	0.39 ± 0.01	0.47 ± 0.01[c] (69)	0.58 ± 0.03[c] (38)	0.63 ± 0.01[c] (52)	19.65
10b	0.33 ± 0.02	0.48 ± 0.02[c] (42)	0.52 ± 0.01[c] (38)	0.66 ± 0.01[c] (34)	
10c	0.37 ± 0.01	0.44 ± 0.01[c] (73)	0.54 ± 0.01[c] (45)	0.62 ± 0.02[c] (50)	15.63
11a	0.34 ± 0.02	0.52 ± 0.03[c] (30)	0.51 ± 0.02[c] (45)	0.52 ± 0.01[c] (64)	16.50
11b	0.40 ± 0.02	0.62 ± 0.01[c] (15)	0.67 ± 0.01[c] (12)	0.72 ± 0.02[c] (36)	
11c	0.38 ± 0.01	0.53 ± 0.02[c] (42)	0.56 ± 0.02[c] (41)	0.58 ± 0.01[c] (60)	15.74
Diclofenac Na	0.37 ± 0.02	0.52 ± 0.01[c] (42)	0.54 ± 0.01[c] (45)	0.52 ± 0.02[c] (66)	13.56

[a] Dose levels, po: test compounds (20 mg / kg b.wt.), diclofenac Na(20 mg / kg b.wt.)
[b] Values are expressed as mean ± S.E. (Number of animals N = 5 rats).
[c] Significantly different compared to corresponding control. $P \leq 0.05$.
[d] Between parentheses (Percentage anti-inflammatory activity, AI %).

Table 2.   Anti-Inflammatory Activity (AI) of the Newly Synthesized Compounds in Formalin-Induced Rat Paw Edema Bioassay (Sub-Acute Inflammatory Model)

Compound[a]	Volume of edema (mL)[b]		
	0	**1st Day**	**8th Day**
Control	0.30 ± 0.01	0.66 ± 0.02	0.85 ± 0.01
7a	0.36 ± 0.01	0.56± 0.02 [c] (44)[d]	0.72 ± 0.01[c] (34)
7b	0.31 ± 0.01	0.57 ± 0.04[c] (21)	0.76 ± 0.01[c] (18)
7c	0.40 ± 0.03	0.62 ± 0.02[c] (38)	0.75 ± 0.03[c] (36)
7d	0.33 ± 0.02	0.59 ± 0.01[c] (21)	0.75 ± 0.02[c] (23)
7e	0.37 ± 0.02	0.54 ± 0.01[c] (52)	0.65 ± 0.01[c] (49)
7f	0.33 ±0.01	0.53 ±0.02 [c] (39)	0.62 ±0.01 [c] (47)
8a	0.33 ±0.02	0.54 ±0.02 [c] (41)	0.71 ±0.02 [c] (30)
8b	0.31 ±0.03	0.56 ±0.02 [c] (24)	0.74±0.03 [c] (21)
8c	0.35 ± 0.01	0.58 ± 0.03[c] (36)	0.73 ± 0.03[c] (30)
8d	0.34 ± 0.01	0.54 ± 0.01[c] (39)	0.67 ± 0.01[c] (40)
8e	0.31 ±0.03	0.57 ±0.01 [c] (27)	0.64 ±0.01 [c] (40)
8f	0.36 ±0.01	0.53 ±0.01 [c] (48)	0.60 ±0.01 [c] (56)
9a	0.30 ± 0.02	0.56 ± 0.02[c] (21)	0.74 ± 0.01[c] (20)
9b	0.32 ± 0.02	0.53 ± 0.02[c] (47)	0.66 ± 0.02[c] (38)
9c	0.32 ±0.02	0.57 ±0.01 [c] (24)	0.72 ±0.01 [c] (27)
10a	0.39 ± 0.01	0.56 ± 0.02[c] (48)	0.63 ± 0.01[c] (56)
10b	0.33± 0.02	0.56± 0.01[c] (36)	0.67± 0.02[c] (38)
10c	0.37 ± 0.01	0.51 ± 0.01[c] (57)	0.60 ± 0.02[c] (58)
11a	0.34 ± 0.02	0.50 ± 0.03[c] (51)	0.64 ± 0.02[c] (45)
11b	0.40 ± 0.02	0.58 ± 0.03[c] (45)	0.69 ± 0.02[c] (47)
11c	0.38± 0.01	0.52± 0.01[c] (57)	0.63± 0.01[c] (54)
Diclofenac Na	0.37 ± 0.02	0.50 ± 0.02[c] (60)	0.61 ± 0.01[c] (56)

[a] Dose levels, po: test compounds (20 mg / kg b.wt.), diclofenac Na(20 mg / kg b.wt.).
[b] Values are expressed as mean ± S.E. (Number of animals N = 5 rats).
[c] Significantly different compared to corresponding control.P ≤ 0.05.
[d] Between parentheses (Percentage anti-inflammatory activity, AI %).

Fig. (3). Anti-inflammatory activity(AI) of the newly synthesized compounds in formalin-induced rat paw edema bioassay (acute inflammatory model).

Fig. (4). Anti-inflammatory Activity of the newly synthesized compounds in formalin-induced rat paw edema bioassay (sub-acute inflammatory model).

would be less effective in controlling chronic inflammatory conditions.

Ulcerogenic Activity

The tested compounds namely; **7f, 8f**, **10a**, **10c**, **11a** and **11c** that exhibited promising anti-inflammatory profiles in the pre-mentioned animal models were further evaluated for their ulcerogenic potential in rats [20]. Gross observation of the isolated rat stomach showed a normal stomach texture for compounds **10a** ,**10c** and **11c** with no observable hyperemia indicating a superior GI safety profile (no ulceration) in the population of the test animals at an oral dose of 300 mg/kg, when administered twice at 2 h intervals in fasted rats. Whereas, compounds **7f**, **8f**, and **11a** showed weak ulceration effect (10%) as diclofenac sodium which was found to cause 10% ulceration under the same experimental conditions.

Acute Toxicity

The same selected compounds; **7f, 8f**, **10a**, **10c**, **11a** and **11c** were further evaluated for their approximate acute lethal

dose ALD_{50} in male rats using a literature method [21]. The results indicated that all of the tested compounds proved to be non-toxic and are well tolerated by the experimental animals. The compounds showed a high safety margin when screened at graded doses (0.1–0.4 g/kg, po), where their ALD_{50} values were found to be > 0.4 g/kg.

Analgesic Activity

The analgesic activity of the synthesized compounds was evaluated using the rat tail withdrawal technique in response to immersion in water at 55 °C [22] using diclofenac Na as a reference drug (20 mg/kg, po). The analgesic activity was measured at 1–4 h time intervals after pain induction. The results were recorded as the average values of five administrations and the percentage increase of the reaction time in comparison with the basal values. The results were presented in (Table **3**) and expressed as means ± SE.

A comparative study of the analgesic activity of the test compounds relative to the reference drug at different time intervals revealed the following:

Table 3.　　**Analgesic Activity of the Newly Synthesized Compounds Using the Rat Tail Withdrawal Technique**

Compound[a]	Reaction Time (sec)[b]			
	0	**1 h**	**2 h**	**4 h**
Control	2.82± 0.10	2.93 ± 0.10	2.95 ± 0.10	2.98 ±0.20
7a	2.92 ± 0.10	3.25 ± 0.20[c] (11)[d]	3.68± 0.20[c] (26)	3.99 ± 0.20[c] (36)
7b	2.75 ± 0.10	3.25 ± 0.20[c] (18)	3.62 ± 0.20[c] (31)	3.74 ± 0.20[c] (36)
7c	2.80 ± 0.10	3.95 ± 0.10[c] (41)	4.02 ± 0.20[c] (43)	4.25 ± 0.30[c] (51)
7d	3.12 ± 0.20	3.83 ± 0.20[c] (22)	3.92 ± 0.20[c] (25)	4.01 ± 0.20[c] (28)
7e	3.01 ± 0.30	4.10 ± 0.20[c] (36)	4.25 ± 0.10[c] (41)	4.46 ± 0.30[c] (48)
7f	3.01 ±0.30	4.11 ±0.20[c] (36)	4.31 ±0.20[c] (43)	4.51 ±0.20[c] (49)
8a	3.10 ±0.20	3.92 ±0.20[c] (26)	4.25 ±0.30[c] (37)	4.60±0.20[c] (48)
8b	2.73 ±0.10	3.15 ±0.10[c] (15)	3.29 ±0.20[c] (20)	3.60 ±0.20[c] (31)
8c	2.80 ± 0.10	3.85 ± 0.10[c] (37)	4.15 ± 0.20[c] (48)	4.42 ± 0.30[c] (57)
8d	3.10 ± 0.20	3.75 ± 0.20[c] (20)	3.93 ± 0.10[c] (26)	4.05 ± 0.30[c] (30)
8e	3.05±0.20	3.82 ±0.30[c] (25)	4.12 ±0.20[c] (35)	4.35 ±0.20[c] (42)
8f	3.08 ±0.10	4.28±0.20[c] (38)	4.38 ±0.20[c] (42)	4.58 ±0.20[c] (48)
9a	3.15 ± 0.10	3.63 ± 0.20[c] (15)	3.85 ± 0.10[c] (22)	3.94 ± 0.10[c] (25)
9b	2.73± 0.20	3.71 ± 0.20[c] (43)	3.92 ± 0.10[c] (43)	3.96 ± 0.20[c] (45)
9c	2.89 ±0.20	3.68 ±0.20[c] (27)	3.79 ±0.20[c] (31)	4.02 ±0.20[c] (39)
10a	2.85 ± 0.20	3.95± 0.10[c] (38)	4.15 ± 0.20[c] (45)	4.35 ± 0.20[c] (52)
10b	2.92 ± 0.10	4.05 ± 0.20[c] (38)	4.12 ± 0.20[c] (41)	4.25 ± 0.20[c] (45)
10c	2.74 ± 0.10	3.94 ± 0.20[c] (43)	4.04 ± 0.30[c] (47)	4.15± 0.30[c] (51)
11a	2.64 ± 0.10	3.24 ± 0.10[c] (22)	3.28 ± 0.20[c] (24)	3.42 ± 0.20[c] (29)
11b	2.82 ± 0.10	3.25 ± 0.10[c] (15)	3.40 ± 0.20[c] (20)	3.69 ± 0.20[c] (30)
11c	3.10 ± 0.10	4.20 ± 0.30[c] (35)	4.42± 0.20[c] (42)	4.71± 0.20[c] (51)
Diclofenac Na	2.78 ± 0.10	3.89 ± 0.30[c] (39)	4.09 ± 0.10[c] (47)	4.33 ± 0.20[c] (55)

[a] Dose levels, po: test compounds (20 mg / kg b.wt.), diclophenac Na (20 mg / kg b.wt.).
[b] Values are expressed as mean ± S.E. (Number of animals N = 5 rats).
[c] Significantly different compared to corresponding control.P ≤ 0.05.
[d] Between parentheses (Percentage analgesic activity).

After 1h, thienotriazolopyrimidines **7c**, **9b** and **10c** exhibited potent analgesic activity (41, 43 and 43% respectively) compared to diclofenac Na (39%), while **7e**, **7f**, **8c**, **8f**, **10a**, **10b** and **11c** showed analgesic activity nearly equivalent (35–38%) to diclofenac Na.

After 2h, the results showed that thienotriazolopyrimidines **8c**, **10a** and **10c** were found to be nearly equipotent (45-48%) to the reference drug (47%), whereas, **7c**, **7e**, **7f**, **8f**, **9b**, **10b** and **11c** showed moderate activity (41-43%).

After 4 h, the thienotriazolopyrimidine **8c** showed higher analgesic activity (57%) compared to the reference drug (55%), whereas **7c**, **10a**, **10c** and **11c** were found to be nearly equipotent or slightly less potent (51-52%) than the reference drug. The rest of the tested compounds showed variable degree of analgesic activities ranging between weak to moderate (25–45%). Results are illustrated by (Fig. **5**).

Collectively, the thienotriazolopyrimidines derivatives **7c**, **8c**, **10a**, **10c** and **11c** were proved to be the most potent analgesic agents with a delayed onset of action (percentage increase of reaction time (51-57% after 4 h) compared to diclofenac Na (percentage increase of reaction time (55% after 4 h).

Docking Studies

Molecular docking studies of compounds **10a, 10c** and **11c** were performed using Molecular Operating Environment (MOE-Dock 2008) module [23] in order to rationalize the obtained biological results. Molecular docking studies further helps in understanding the various interactions between the ligand and enzyme active site in detail. The determination of the three-dimensional co-crystal structure of COX-2 complex with Diclofenac Na (Fig. **6**; PDB ID code: **1PXX**) has led to the development of a model for the topography of the NSAIDs binding site in human COX-2 [26]. Therefore, herein we performed the docking studies using this COX-2 co-crystal structure with Diclofenac Na as a template. (Figs. **7-9**) show the binding interactions of compounds **10a, 10c** and **11c** to the active site of COX-2, respectively, where they

exhibited some similar interactions as with Diclofenac Na. Compound **10a** displayed three hydrogen bond interactions with Arg 120 and Tyr 355 in addition to hydrophobic interactions with His 90, Arg 120, Val 349, Leu 352, Ser 353, Tyr 355, Phe 381, Leu 384, Tyr 385, Trp 387, Arg 513, Phe 518, Met 522, Val 523, Gly 526, Ala 527, Ser 530 and Leu 531. On the other hand, compound **10c** showed four hydrogen bond interactions with Tyr 355 and Arg 120, in addition to hydrophobic interactions with His 90, Met 113, Arg 120, Ile 345, Val 349, Leu 352, Ser 353, Tyr 355, Leu 359, Phe 381, Leu 384, Tyr 385, Trp 387, Arg 513, Phe 518, Met 522, Val 523, Gly 526, Ala 527 and Leu 531. Compound **11c** displayed two hydrogen bond interactions with Tyr 355 and Ser 530, in addition to hydrophobic interactions with His 90, Leu 93, Tyr 115, Val 116, Arg 120, Val 349, Leu 352, Ser 353, Tyr 355, Leu 359, Leu 384, Tyr 385, Trp 387, Phe 518, Met 522, Val 523, Gly 526, Ala 527, Ser 530 and Leu 531.

CONCLUSION

The present study reports the synthesis and biological evaluation of 21 newly synthesized thienotriazolopyrimidines as anti-inflammatory and analgesic agents. The obtained results clearly revealed that most of the tested compounds showed better activity at the acute inflammatory model than the subacute one in addition to good analgesic profile. Moreover, the 8-{[2-(phenylamino)-2-oxoethyl]sulfonyl}**8a** and the 8-{[2-(4-methoxyphenyl)ethylamino)-2-oxoethyl] sulfonyl}**8f** derivative exhibited better anti-inflammatory activity at the acute model than its sulfanyl analogs **7a** and **7f** while the 8-methylsulfonyl **10a** and 8-benzylsulfonyl **10c** derivatives exhibited better anti-inflammatory activity at the acute model than its corresponding sulfanyl analoges **9a** and **9c**. Inaddition, replacement of the S methyl group at compound **9a** with secondary amines enhances the anti-inflammatory activity specially the N-phenylpiperazine derivative **11c**. Collectively, thienotriazolopyrimidines **10a**, **10c** and **11c** were proved to display distinctive anti-inflammatory activity at both models as well as good analgesic profile with a delayed onset of action.

Fig. (5). Analgesic activity of the newly synthesized compounds using the rat tail withdrawl technique.

Fig. (6). 3D View from a molecular modeling study, of the minimum-energy structure of the complex of Diclofenac Na docked in COX-2 (PDB ID: 1PXX). Viewed using Molecular Operating Environment (MOE) module.

Fig. (7). 3D View from a molecular modeling study, of the minimum-energy structure of the complex of **10a** docked in COX-2 (PDB ID: 1PXX). Viewed using Molecular Operating Environment (MOE) module.

Fig. (8). 3D View from a molecular modeling study, of the minimum-energy structure of the complex of **10c** docked in COX-2 (PDB ID: 1PXX). Viewed using Molecular Operating Environment (MOE) module.

Fig. (9). 3D View from a molecular modeling study, of the minimum-energy structure of the complex of **11c** docked in COX-2 (PDB ID: 1PXX). Viewed using Molecular Operating Environment (MOE) module.

Additionally, the active compounds revealed good GI safety profile and are well tolerated by experimental animals with high safety margin (ALD$_{50}$ > 0.4 g/kg**).** Docking studies for compounds **10a, 10c** and **11c** with COX-2 enzyme (PDB ID code: **1PXX**) showed good binding profile. Finally, these compounds represent new structure scaffolds that could be further optimized for future development of more potent anti-inflammatory and analgesic agents.

CONFLICT OF INTEREST

The authors declared no conflicts of interest. The authors alone are responsible for the content and writing of the paper.

ACKNOWLEDGEMENTS

REFERENCES

[1]   Bombardier, C.; Laine, L.; Reicin, A.; Shapiro, D.; Burgos-Vargas, R.; Davis, B.; Day, R.; Bosi Ferraz, M.; Hawkey, C.J.; Hochberg, M.C.; Kvien, T.K.; Schnitzer, T.J. Comparison of upper gastrointestinal toxicity of rofecoxib and naproxen in patients with rheumatoid arthritis. *N. Engl. J. Med.,* **2000,** *343,* 1520-1528.

[2]   Silverstein, F.E.; Faich, G.; Goldstein, J.L.; Simon, L.S.; Pincus, T.; Whelton, A.; Makuch, R.; Eisen, G.; Agrawal, N.M.; Stenson, W.F.; Burr, A.M.; Zhao, W.W.; Kent, J.D.; Lefkowith, J.B.; Verburg, K.M.; Gies, G.S. Gastrointestinal toxicity with celecoxib vs nonsteroidal anti-inflammatory Drugs for osteoarthritis and rheumatoid arthritis: the class study. A randomized controlled trial. *J. Am. Med. Assoc.,* **2000,** *284,* 1247-1255.

[3]   Rashad, A.E.; Shamroukh, A.H.; Abdel-Megeid, R.E.; Mostafa, A.; El-Shesheny, R.; Kandeil, A.; Ali, M.A.; Banert, K. Synthesis and screening of some novel fused thiophene and thienopyrimidine derivatives for anti-avian influenza virus (H5N1) activity. *Eur. J. Med. Chem.,* **2010,** 45, 5251-5257.

[4]   Rashad, A.E.; Ali, M.A. Synthesis and antiviral screening of some thieno[2,3-d] pyrimidine nucleosides. *Nucleosides Nucleotides,* **2006**, *25,* 17-28.

[5]   Habib, N. S.; Soliman, R.; El-Tombary, A. A.; El-Hawash, S. A.; Shaaban, O. G. Synthesis and biological evaluation of novel series of thieno[2,3-d]pyrimidine derivatives as anticancer and antimicrobial agents. *Med. Chem. Res.,* **2013,** *22,* 3289-3308.

[6]   Soliman, R.; Habib, N.S.; El-Tombary, A.A.; El- Hawash, S.A.; Shaaban, O.G. Synthesis of tetrahydrobenzothieno[2,3-d]pyrimidine and tetrahydro-benzothieno[3,2-e]-[1,2,4]triazolo[4,3-c] pyrimidine Derivative as potential antimicrobial agents. *Sci. Pharm.,* **2009,** *77,* 755-773.

[7]   Bhuiyan, M.D.; Rahman, K.M.; Hossain, M.D.; Rahim, A.; Hossain, M.I.; Abu Naser, M. Synthesis and antimicrobial evaluation of some new thienopyrimidine derivatives. *Acta. Pharm.,* **2006,** *56,* 441-450.

[8]   Hegab, M.I.; Hassan, N.A.; Rashad, A.E.; Fahmy, A.A.; Abdel-Megeid, F.M.E. Synthesis, reactions, and antimicrobial activity of some fused thieno[2,3-*d*]pyrimidine derivatives. *Phosphorus, Sulfur Silicon,* **2007,** *182,* 1535-1556.

[9]   Alqasoumi, S.I.; Ragab, F.A.; Alafeefy, A.M.; Galal, M.; Ghorab, M.M. Radioprotective and antitumor activity of some novel amino acids and imidazoles containing thieno[2,3-d]pyrimidine moiety. *Phosphorus,Sulfur Silicon,* **2009,** *184,* 3241-3257.

[10]   Munchhof, M. J.; Beebe, J. S.; Casavant, J. M.; Cooper, B. A.; Doty, J. L.; Higdon, R. C.; Hillerman, S. M.; Soderstrom, C. I.; Knauth, E. A.; Marx, M. A.; Rossi, A. M.; Sobolov, S. B.; Sun, J. Design and SAR of thienopyrimidine and thienopyridine inhibitors of VEGFR-2 kinase activity. *Bioorg. Med. Chem. Lett.,* **2004**, *14*, 21-24.

[11]   Sleebs, B. E.; Nikolakopoulos, G.; Street, I. P.; Falk, H.; Baell, J. B. Identification of 5,6-substituted 4-aminothieno[2,3-d]pyrimidines as LIMK1 inhibitors. *Bioorg. Med. Chem. Lett.,* **2011**, *21*, 5992-5994.

[12]   Alagarsamy, V.; Vijayakumar, S.; Raja Solomon, V. Synthesis of 2-mercapto-3-substituted-5,6-dimethylthieno[2,3-d]pyrimidin-4(3H)-ones as new analgesic, anti-inflammatory agents. *Biomed. Pharmacother.*, **2007**, *61*, 285-291.

[13]   El-Ansary, A.K.; Omar, A.H. Synthesis and anti-inflammatory activity of some thieno [2,3-d] pyrimidinone derivatives. *Bull. Fac. Pharm. Cairo Univ.* **2001**, *39*, 17-25.

[14]   Alagarsamy, V.; Meena, S.; Ramseshu, K.V.; Solomon, V.R.; Thirumurugan, K.; Dhanabal, K.; Murugan, M. Synthesis, analgesic, anti-inflammatory, ulcerogenic index and antibacterial activities of novel 2-methylthio-3-substituted-5,6,7,8-tetrahydrobenzo (b) thieno[2,3-d]pyrimidin-4(3H)-ones. *Eur. J. Med. Chem.*, **2006**, *41*, 1293-1300.

[15]   Ashalatha, B.V.; Narayana, B.; Vijaya Raj, K.K.; Suchetha Kumari, N. Synthesis of some new bioactive 3-amino-2-mercapto-5,6,7,8-tetrahydro [2,3-d] benzothieno [2,3-d] pyrimidin-4(3H)-one derivatives. *Eur. J. Med. Chem.*, **2007**, *42*, 719-728.

[16]   Modica, M.; Santagati, M.; Santagati, A.; Cutuli, V.; Mangano, N.; Caruso, A. Synthesis of new [1,3,4]thiadiazolo[3,2-a]thieno[2,3-d]pyrimidinone derivatives with antiinflammatory activity. *Pharmazie*, **2000**, *55*, 500-502.

[17]   Rizk, O.H.; Shaaban, O.G.; El-Ashmawy, I.M. Design, synthesis and biological evaluation of some novel thienopyrimidines and fused thienopyrimidines as anti-inflammatory agents. *Eur. J. Med. Chem.,* **2012,** *55,* 85-93.

[18]   Ashour, H.M.A.; Shaaban, O.G.; Rizk, O. H.; El-Ashmawy, I. M. Synthesis and biological evaluation of thieno

[2′,3′:4,5]pyrimido[1,2-b][1,2,4]triazines and thieno[2,3-d][1,2,4]triazolo[1,5-a] pyrimidines as anti-inflammatory and analgesic agents. *Eur. J. Med. Chem.*, **2013**, *4*, 341-351

[19]   Hosseinzadeh, H.; Younesi, H.M. Antinociceptive and anti-inflammatory effects of Crocus sativus L. stigma and petal extracts in mice. *BMC Pharmacol.*, **2002**, *2*, 1-2.

[20]   Daidone, G.; Maggio, B.; Raffa, D.; Plescia, S.; Bajardi, M.L.; Caruso, A.; Cutuli,V.M.C.; Amico-Roxas, M. Synthesis and pharmacological study of ethyl 1-methyl-5-[2-substituted-4-oxo-3(4H)-quinazolinyl]-1H-pyrazole-4-acetates. *Eur. J. Med. Chem.*, **1994**, *29*, 707-711.

[21]   Verma, M.; Tripathi, M.; Saxena, A.K.; Shanker, K. Antiinflammatory activity of novel indole derivatives. *Eur. J. Med. Chem.*, **1994**, *29*, 941-946.

[22]   Jansem P.A.J.; Jagenav, A.H. A new series of potent analgesics: Dextro-2,2-diphenyl-3-methyl-4- morpholinobutyryl pyrrolidine and related amides. *J. Pharm. Pharmacol.,* **1959**, *9*, 381.

[23]   Molecular Operating Environment (MOE) version. Chemical Computing Group, Inc, Montréal, Canada, **2008**. http://www.chemcomp.com

[24]   Baraldi, P. G.; Preti, D.; Tabrizi, M. A.; Fruttarolo, F.; Saponaro, G.; Baraldi, S.; Romagnoli, R.; Moorman, A. R.; Gessi, S. Varani, K.; Borea P. A. N[6]-[(Hetero)aryl/(cyclo)alkyl-carbamoyl-methoxy-phenyl]-(2-chloro)-5-*N*-ethylcarboxamido-adenosines: The first example of adenosine-related structures with potent agonist activity at the human A_{2B} adenosine receptor. *Bioorg. Med. Chem.*, **2007**, *15*, 2514-2527.

[25]   El-Emam A. A.; Ibrahim, T.M. Synthesis and anti-inflammatory and analgesic activity of some 3-(1-adamantyl)-4-substituted-5-mercapto-1,2,4-triazoles. *Arzneim. Forsch.*, **1991,** *41*, 1260.

[26]   Rowlinson, S.W.; Kiefer, J.R.; Prusakiewicz, J.J.; Pawlitz, J.L.; Kozak, K.R.; Kalgutkar, A.S.; Stallings, W.C.; Kurumbail, R.G.; Marnett, L.J. A novel mechanism of cyclooxygenase-2 inhibition involving interactions with Ser-530 and Tyr-385. *J. Biol. Chem.,* **2003,** *46*, 45763-9.